Evidence Review
Ellis et al. (2022) — Comprehensive meta-analysis of blood pressure and cardiometabolic markers [1]
This systematic review and meta-analysis searched Web of Science, Cochrane, Ovid (MEDLINE, Embase, AMED), and Scopus up to June 2021, including 17 chronic randomized controlled trials. For blood pressure, the pooled analysis found significant reductions: systolic BP −7.1 mmHg (95% CI: −10.0 to −4.3; p<0.001) and diastolic BP −3.5 mmHg (95% CI: −5.3 to −1.7; p<0.001). Subgroup analyses revealed that the blood pressure-lowering effect was most pronounced in trials lasting more than four weeks and in participants with higher baseline systolic blood pressure (>130 mmHg). Effects on lipids were less consistent: significant LDL reduction was observed, but HDL and triglycerides were not consistently improved across trials. Fasting plasma glucose was reduced significantly in a subset of trials. The authors noted moderate to high heterogeneity across trials, attributed to differences in dose, preparation, study population, and duration — which is typical for herbal intervention trials. Overall evidence quality was rated moderate. This meta-analysis is the most comprehensive to date covering multiple cardiometabolic outcomes.
Negida et al. (2022) — Meta-analysis specifically in hypertensive patients [2]
This meta-analysis analyzed 13 randomized controlled trials involving 1,205 participants specifically diagnosed with mild-to-moderate hypertension or metabolic syndrome. The pooled blood pressure reductions were −6.67 mmHg systolic (95% CI: not reported in excerpts; p=0.004) and −4.35 mmHg diastolic (p=0.02) compared to placebo. A key finding of this meta-analysis was that the blood pressure effects were statistically significant in participants with hypertension alone but not in those with hypertension combined with metabolic syndrome — suggesting that metabolic complexity or concurrent medications may attenuate the effect. The authors concluded that Hibiscus sabdariffa is a reasonable complementary approach for mild-to-moderate hypertension and called for standardized reporting of dose and preparation in future trials.
McKay et al. (2010) — Foundational randomized controlled trial [3]
This randomized, double-blind, placebo-controlled trial enrolled 65 pre- and mildly hypertensive adults (ages 30–70, not taking antihypertensive medications) at Tufts University. Participants were randomized to drink 3 cups daily of hibiscus tisane or placebo hibiscus-flavored beverage (matched for color and taste) for 6 weeks. Primary outcome was change in systolic blood pressure. The hibiscus group showed a significant reduction in systolic blood pressure of −6.9 mmHg from baseline compared to −1.3 mmHg in the placebo group (net difference −5.6 mmHg; p=0.03). Diastolic blood pressure was also reduced, though the diastolic change did not differ significantly from placebo. Participants with higher baseline systolic blood pressure (≥129 mmHg) showed greater reductions: −13.2 mmHg. No significant adverse effects were reported. This trial was notable for its methodological rigor — double blinding with a matched placebo beverage is challenging for strongly flavored herbal teas — and for establishing the three-cup daily dose that is now most commonly studied.
Najafpour Boushehri et al. (2020) — Multi-outcome cardiovascular meta-analysis [4]
This meta-analysis searched multiple databases from inception to June 2019, identifying 7 eligible randomized clinical trials with 362 participants. The primary focus was on lipid profiles, fasting plasma glucose, and blood pressure. Pooled results showed significant reductions in fasting plasma glucose (−3.67 mg/dL; 95% CI: −7.07, −0.27; I²=37%), systolic blood pressure (−4.71 mmHg; 95% CI: −7.87, −1.55; I²=53%), and diastolic blood pressure. Effects on total cholesterol, triglycerides, and HDL did not reach significance when pooled, though most individual trials showed favorable trends. The authors noted that the glycemic effect, while statistically significant, is modest in absolute terms and the included trials were mostly short-duration with small sample sizes. The I² value of 53% for systolic blood pressure indicates moderate heterogeneity, consistent with variability in hibiscus preparation and participant characteristics across included trials.
Mozaffari-Khosravi et al. (2009) — Lipid effects in type 2 diabetics [6]
This sequential randomized controlled trial enrolled 60 patients with type 2 diabetes, randomizing them to either sour tea (Hibiscus sabdariffa) or black tea consumed twice daily for one month. Fifty-three participants completed the study. In the hibiscus group, significant changes from baseline were observed: HDL-cholesterol increased (p=0.002), while total cholesterol, LDL-cholesterol, triglycerides, and Apo-B100 all decreased significantly. The black tea control group showed no significant lipid changes. Effect sizes for LDL reduction were clinically meaningful. This trial is important because it used an active comparator (black tea, also a polyphenol-rich beverage) rather than a plain placebo, making the hibiscus-specific effects more convincing. Limitations include the relatively short duration (one month) and open-label design for beverage type.
Chang et al. (2014) — Liver steatosis in overweight humans [5]
This 12-week randomized trial enrolled 36 participants with BMI ≥27 and ages 18–65, randomized to Hibiscus sabdariffa extract (HSE) or control. The HSE group showed significant reductions in body weight, BMI, body fat percentage, and waist-to-hip ratio. Critically, ultrasound-assessed liver steatosis improved in the HSE group compared to controls. This is one of few human trials specifically examining hibiscus effects on the liver, and the findings are consistent with mechanistic animal data showing that hibiscus anthocyanins downregulate fatty acid synthesis genes (SREBP-1c, PPAR-γ) in liver tissue, reduce inflammatory cytokines, and increase antioxidant enzyme activity. The trial was well tolerated with no adverse effects reported.
Strength of evidence summary: Hibiscus has unusually strong clinical evidence for an herbal tea, particularly for blood pressure reduction. Two recent meta-analyses of 13–17 RCTs each confirm consistent, meaningful antihypertensive effects. Individual trial results (including the rigorously blinded McKay et al. study) are coherent with the mechanistic understanding of ACE inhibition and vasodilation. Blood sugar and cholesterol benefits are supported by meta-analysis but with smaller pooled effect sizes and more heterogeneity across trials. The liver steatosis finding is early-stage for humans but mechanistically plausible. Overall: strong evidence for blood pressure lowering in hypertensive individuals, moderate evidence for cholesterol and glycemic improvement in metabolically challenged populations, and preliminary human evidence for liver support. The main gaps are long-term safety data at supplemental doses and trials in general healthy populations for metabolic effects.